Invasive Strategy Offers No Added Benefit in Low-Risk SCAD Patients and Raises Bleeding Risk: Study Finds

Written By :  Medha Baranwal
Medically Reviewed By :  Dr. Kamal Kant Kohli
Published On 2025-06-10 16:00 GMT   |   Update On 2025-06-10 16:00 GMT

China: A recent risk-stratification-based study has brought new insight into managing stable coronary artery disease (SCAD), highlighting that an invasive approach may not offer universal benefits over conservative treatment—except in patients identified as moderate-to-high risk.

In patients with SCAD, percutaneous coronary intervention (PCI) did not significantly reduce ischemic events compared to conservative management and was associated with an increased risk of bleeding (hazard ratio 1.59), the researchers reported in BMC Medicine. However, among those classified as moderate-to-high risk, PCI was linked to a 33% reduction in ischemic events and a 27% decrease in all-cause mortality without an accompanying rise in bleeding risk. These findings suggest that risk stratification could be crucial in guiding optimal treatment strategies for SCAD.

The long-term benefits of percutaneous coronary intervention in patients with stable coronary artery disease, as compared to conservative management, have remained a topic of ongoing debate. To address this uncertainty, Zizhao Qi, Department of Cardiology, The Second Affiliated Hospital of Harbin Medical University, Harbin, China, and colleagues aimed to assess the impact of an initial invasive strategy versus a conservative approach on long-term clinical outcomes in SCAD patients, using risk stratification to identify which subgroups may benefit most from each treatment pathway.

For this purpose, the researchers conducted a sub-analysis of the multicenter, observational OPT-CAD (Optimal antiPlatelet Therapy for Chinese patients with Coronary Artery Disease) study. They compared clinical outcomes in SCAD patients who were initially managed with either PCI (invasive strategy) or conservative treatment, based on their risk levels determined by the OPT-CAD score.

The primary outcome was the occurrence of ischemic events over five years, including cardiac death, myocardial infarction, and ischemic stroke. Secondary outcomes included all-cause mortality and major bleeding events, defined as BARC types 2, 3, or 5.

The study led to the following findings:

  • The study included 1767 patients (58.0%) in the conservative group and 1278 patients (42.0%) in the invasive group.
  • Overall, the invasive strategy did not lower the risk of ischemic events compared to the conservative approach.
  • However, it was linked to a higher risk of BARC type 2, 3, or 5 bleeding (adjusted HR 1.59).
  • In the low-risk subset (N = 2030), outcomes were similar, with no added benefit from the invasive strategy.
  • In the moderate-to-high-risk subset (N = 1015), the invasive approach significantly reduced the risk of ischemic events (HR 0.67).
  • A trend toward reduced all-cause mortality was also observed in this group (HR 0.73).
  • No increased risk of bleeding was noted in moderate-to-high-risk patients receiving invasive treatment.

“In patients with stable coronary artery disease, an initial invasive strategy did not provide additional clinical benefit over conservative management and was associated with a higher risk of bleeding,” the researchers noted. “However, among those classified as moderate-to-high risk based on the OPT-CAD score, the invasive approach was linked to a reduction in ischemic events without an increased risk of bleeding”

“These findings underscore the potential utility of the OPT-CAD score in guiding personalized treatment decisions for patients with SCAD,” they concluded.

Reference:

Qi, Z., Qiu, M., Xu, Y. et al. Comparative outcomes of invasive versus conservative strategy in stable coronary artery disease patients: a risk-stratification-based hypothesis-generative study. BMC Med 23, 199 (2025). https://doi.org/10.1186/s12916-025-04020-2


Tags:    
Article Source : BMC Medicine

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News